The ins and outs of selective kinase inhibitor development.

[1]  S. Knapp,et al.  A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics , 2014, Nature chemical biology.

[2]  Stefan Knapp,et al.  Recently targeted kinases and their inhibitors-the path to clinical trials. , 2014, Current opinion in pharmacology.

[3]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[4]  S. Knapp,et al.  Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.

[5]  L. Wodicka,et al.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.

[6]  S. Knapp,et al.  Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. , 2013, Investigative ophthalmology & visual science.

[7]  Nathanael S Gray,et al.  Developing irreversible inhibitors of the protein kinase cysteinome. , 2013, Chemistry & biology.

[8]  L. Shewchuk,et al.  Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). , 2012, Journal of medicinal chemistry.

[9]  Simeon S. Andrews,et al.  Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. , 2012, ACS chemical biology.

[10]  Wolfgang Albrecht,et al.  Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. , 2012, Nature chemical biology.

[11]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[13]  Cristiano R. W. Guimaraes,et al.  Understanding the Impact of the P-loop Conformation on Kinase Selectivity , 2011, J. Chem. Inf. Model..

[14]  Yoshiaki Washio,et al.  Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. , 2011, Chemistry & biology.

[15]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.

[16]  S. Knapp,et al.  The (un)targeted cancer kinome. , 2010, Nature chemical biology.

[17]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[18]  D. Hirschberg,et al.  Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. , 2009, Nature chemical biology.

[19]  Stefan Knapp,et al.  Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites , 2008, The EMBO journal.

[20]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[21]  S. Knapp,et al.  Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.

[22]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[23]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[24]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[25]  J. Zheng,et al.  Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.